Monday, October 2, 2023
Monday, October 2, 2023

Contact: 561.316.3330

3 UnityPoint Health Hospitals Gain Increased Efficiencies With Carestream Health’s DRX-Evolution Plus and DRX-Revolution Diagnostic Imaging Systems

September 1, 2020

3 UnityPoint Health hospitals in Illinois experienced smoother workflow, an uptick in efficiency and excellent image quality with Carestream Health’s DRX-Evolution Plus and DRX-Revolution diagnostic imaging systems. The news was announced today by Carestream Health, a leader in this field.

Carestream Health Drx Evolution Piu 2

“The workflow is more efficient, it’s faster with these new systems. We see a more productive use of time, which means faster turnaround for both our clinicians and our patients,” said Kevin Baker, Regional Director of Medical Imaging for UnityPoint Health’s Methodist, Pekin and Proctor hospitals. “There are different ways to use the equipment that we didn’t have before with other units.”

Carestream’s X-Factor platform enables facilities to share the same wireless detector seamlessly across all Carestream DRX products and allows technologists to move easily between different systems.

With the CARESTREAM DRX-Evolution Plus System, UnityPoint’s emergency departments perform a variety of general radiographic exams with ease. Its user-friendly software along with the ability to operate the system in various positions for examination empower hospitals to expand their imaging solutions and enhance productivity. The DRX-Evolution Plus (see video link) enables technologists to capture a wide array of X-ray images, including cross-table, spine, abdomen, long-length and scoliosis exams.

“The digital image quality is above and beyond,” Mr. Baker said. “We are able to tweak and substitute protocols if needed. Service is prompt and we’ve been very happy with that.”

On the portable imaging front, the CARESTREAM DRX-Revolution Mobile X-ray System is used throughout UnityPoint’s hospitals as needed, from patient rooms and the Intensive Care Unit to operating rooms. Designed to quietly navigate hallways and work in tight spaces, the DRX-Revolution provides high-quality image capture at the patient’s bedside.

“The mobile X-ray system is our primary portable unit for all exams. The image quality is preferred over other units by our radiologists,” Mr. Baker said.

With these new medical imaging systems, having the ability to work with a lower radiation dose and still achieve high-quality digital images has been especially useful at UnityPoint. In addition, quick access to technical support makes it easy for the hospitals to work without significant interruption in workflow.

“We want to use as little radiation as possible and get good image quality,” Mr. Baker said. “Carestream’s ability to work with us and make the adjustments that we want is very helpful.”

Establishing a trusted relationship with Carestream—from sales to customer support—has been instrumental in the expansive and cohesive use of the digital imaging systems at UnityPoint.

“It really starts with ‘Do you trust the company? Do you trust what they tell you? Has it been proven over time?’ Building a partner-type relationship is critical,” Mr. Baker added. “They understand the challenges we face with funding and how we need to get the most with our dollar. They are selling products that we need and not pushing products that we don’t. To me, that’s invaluable.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy